{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:12:52Z","timestamp":1789132372578,"version":"build-2803163510"},"reference-count":356,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["SALUD-2017-1-289800"],"award-info":[{"award-number":["SALUD-2017-1-289800"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007045","name":"Secretar\u00eda de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n del Distrito Federal","doi-asserted-by":"publisher","award":["0048\/2014"],"award-info":[{"award-number":["0048\/2014"]}],"id":[{"id":"10.13039\/501100007045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00195","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T05:19:37Z","timestamp":1587446377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics"],"prefix":"10.3389","volume":"11","author":[{"given":"Samantha","family":"Alvarez-Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Medina-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Saracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hurtado-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Maldonado-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Becerril-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenin","family":"Pav\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2398212818817498","DOI":"10.1177\/2398212818817498","article-title":"The development of antipsychotic drugs","volume":"2","author":"Cunningham Owens","year":"2018","journal-title":"Brain Neurosci Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu Rev Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","article-title":"Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","volume":"844","author":"Singh","year":"2019","journal-title":"Eur J Pharmacol."},{"key":"B5","volume-title":"Antipsychotic Medications","author":"Chokhawala","year":"2019"},{"key":"B6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/cap.2018.0037","article-title":"A focused review on the treatment of pediatric patients with atypical antipsychotics","volume":"28","author":"Lee","year":"2018","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.2147\/NDT.S208061","article-title":"Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review","volume":"15","author":"Xu","year":"2019","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125317693200","article-title":"Atypical antipsychotics: recent research findings and applications to clinical practice: proceedings of a symposium presented at the 29th Annual European college of neuropsychopharmacology congress, 19 September 2016, Vienna, Austria","volume":"7","author":"Murray","year":"2017","journal-title":"Ther Adv Psychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.9740\/mhc.2016.07.178","article-title":"Atypical antipsychotics: a review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects","volume":"6","author":"Wei Xin Chong","year":"2016","journal-title":"Ment Heal Clin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00164.2018","article-title":"Antipsychotics and glucose metabolism: how brain and body collide","volume":"316","author":"Kowalchuk","year":"2019","journal-title":"Am J Physiol Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-12668-1_1","article-title":"Insulin resistance in schizophrenia","volume":"1134","author":"Guest","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/J.NEUBIOREV.2019.05.018","article-title":"Appetite regulating hormones in first-episode psychosis: a systematic review and meta-analysis","volume":"102","author":"Misiak","year":"2019","journal-title":"Neurosci Biobehav Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4306\/pi.2017.14.5.703","article-title":"Evidence for hypothalamus-pituitary-adrenal axis and immune alterations at prodrome of psychosis in males","volume":"14","author":"Karanikas","year":"2017","journal-title":"Psychiatry Investig."},{"key":"B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.imlet.2011.06.011","article-title":"Antipsychotic drugs suppress the AKT\/NF-\u03baB pathway and regulate the differentiation of T-cell subsets","volume":"140","author":"Chen","year":"2011","journal-title":"Immunol Lett."},{"key":"B16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.intimp.2011.11.011","article-title":"Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-\u03b1-directed cell apoptosis in neutrophils","volume":"12","author":"Chen","year":"2012","journal-title":"Int Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3109\/08923973.2011.651535","article-title":"Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-\u03b3 production in peripheral blood mononuclear cells","volume":"34","author":"Chen","year":"2012","journal-title":"Immunopharmacol Immunotoxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/J.PSYCHRES.2017.07.002","article-title":"Changes in the cytokine profile in first-episode, drug-na\u00efve patients with psychosis after short-term antipsychotic treatment","volume":"256","author":"Petrikis","year":"2017","journal-title":"Psychiatry Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neubiorev.2017.03.003","article-title":"Acute variations of cytokine levels after antipsychotic treatment in drug-na\u00efve subjects with a first-episode psychosis: a meta-analysis","volume":"77","author":"Capuzzi","year":"2017","journal-title":"Neurosci Biobehav Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00213-019-5185-8","article-title":"Psychotropics and the microbiome: a chamber of secrets","volume":"236","author":"Cussotto","year":"2019","journal-title":"Psychopharmacology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3390\/ijms18102174","article-title":"Unresolved issues for utilization of atypical antipsychotics in schizophrenia: antipsychotic polypharmacy and metabolic syndrome","volume":"18","author":"Jeon","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment \u2013 pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"17","author":"Fleischhacker","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/2046-4053-3-133","article-title":"Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis","volume":"3","author":"Liu","year":"2014","journal-title":"Syst Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","article-title":"Polypharmacy in schizophrenia","volume":"126","author":"Baandrup","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3160486","DOI":"10.1155\/2016\/3160486","article-title":"Immunomodulatory effects mediated by dopamine","volume":"2016","author":"Arreola","year":"2016","journal-title":"J Immunol Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"354957","DOI":"10.1155\/2015\/354957","article-title":"Immunomodulatory effects mediated by serotonin","volume":"2015","author":"Arreola","year":"2015","journal-title":"J Immunol Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/MPA.0000000000000357","article-title":"Pancreatic endocrine effects of dopamine receptors in human islet cells","volume":"44","author":"Zhang","year":"2015","journal-title":"Pancreas."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1517\/14656566.2012.686169","article-title":"A review of olanzapine pamoate","volume":"13","author":"Chue","year":"2012","journal-title":"Expert Opin Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT 7) and 5-HT 1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/J.EJMECH.2018.01.002","article-title":"Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects","volume":"145","author":"Zajdel","year":"2018","journal-title":"Eur J Med Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1021\/jm049632c","article-title":"Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents","volume":"48","author":"Fern\u00e1ndez","year":"2005","journal-title":"J Med Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.1016\/j.bmc.2008.06.030","article-title":"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one","volume":"16","author":"Ablordeppey","year":"2008","journal-title":"Bioorg Med Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1017\/S1092852912000764","article-title":"Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial","volume":"18","author":"Cutler","year":"2013","journal-title":"CNS Spectr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2147\/NDT.S49028","article-title":"Clozapine reinitiation following a \u201cred result\u201d secondary to chemotherapy","volume":"9","author":"Munshi","year":"2013","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2165\/00003495-200767070-00008","article-title":"Quetiapine: a review of its use in the treatment of bipolar depression","volume":"67","author":"Keating","year":"2007","journal-title":"Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/2045125311430112","article-title":"Receptor mechanisms of antipsychotic drug action in bipolar disorder \u2013 focus on asenapine","volume":"1","author":"Reynolds","year":"2011","journal-title":"Ther Adv Psychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert Opin Investig Drugs."},{"key":"B41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","article-title":"Aripiprazole: profile on efficacy and safety","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opin Pharmacother."},{"key":"B43","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1586\/ern.12.137","article-title":"A review of paliperidone palmitate","volume":"12","author":"Chue","year":"2012","journal-title":"Expert Rev Neurother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2165\/11634440","article-title":"Paliperidone: a review of clinical trial data and clinical implications","volume":"32","author":"Wang","year":"2012","journal-title":"Clin Drug Investig."},{"key":"B46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","article-title":"Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders","volume":"25","author":"Kalkman","year":"2001","journal-title":"Neuropsychopharmacology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0024-3205(03)00419-3","article-title":"Functional characterization of the novel antipsychotic iloperidone at human D2, D3, \u03b12C, 5-HT6, and 5-HT1A receptors","volume":"73","author":"Kalkman","year":"2003","journal-title":"Life Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/107385840000600408","article-title":"The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?","volume":"6","author":"Roth","year":"2000","journal-title":"Neuroscientist."},{"key":"B50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0014-2999(96)00840-0","article-title":"Iloperidone binding to human and rat dopamine and 5-HT receptors","volume":"317","author":"Kongsamut","year":"1996","journal-title":"Eur J Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/dddt.s6443","article-title":"New atypical antipsychotics for schizophrenia: iloperidone","volume":"4","author":"Caccia","year":"2010","journal-title":"Drug Des Devel Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1568007024606221","article-title":"Current status of antipsychotic treatment","volume":"1","author":"Conley","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord."},{"key":"B53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1476-5381.2012.02223.x","article-title":"New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2","volume":"168","author":"Kenakin","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1074\/jbc.M111.301820","article-title":"Cell contact-dependent functional selectivity of \u03b22-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation","volume":"287","author":"Kaya","year":"2012","journal-title":"J Biol Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17460441.2017.1297417","article-title":"Signaling bias in drug discovery","volume":"12","author":"Kenakin","year":"2017","journal-title":"Expert Opin Drug Discov."},{"key":"B58","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","article-title":"Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls","volume":"33","author":"Hahn","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther Adv drug Saf."},{"key":"B60","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/15287394.2018.1495587","article-title":"Clozapine, ziprasidone, and sertindole-induced morphological changes in the rat heart and their relationship to antioxidant enzymes function","volume":"81","author":"Nikoli\u0107-Koki\u0107","year":"2018","journal-title":"J Toxicol Environ Health A."},{"key":"B61","doi-asserted-by":"publisher","first-page":"107717","DOI":"10.1016\/j.neuropharm.2019.107717","article-title":"A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models","volume":"23","author":"Yuen","year":"2019","journal-title":"Neuropharmacology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.schres.2016.10.012","article-title":"Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine","volume":"181","author":"Nakazawa","year":"2017","journal-title":"Schizophr Res."},{"key":"B63","unstructured":"Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysisS2634\n            PotvinS\n            ZhornitskyS\n            StipE\n          25886677Can J Psychiatry.602015"},{"key":"B64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000100981","article-title":"Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation","volume":"85","author":"Tulipano","year":"2007","journal-title":"Neuroendocrinology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine","volume":"8","author":"Boyda","year":"2013","journal-title":"PLoS ONE."},{"key":"B68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1055\/s-0028-1100425","article-title":"Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study","volume":"42","author":"Tschoner","year":"2009","journal-title":"Pharmacopsychiatry."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor","volume":"27","author":"Weston-Green","year":"2013","journal-title":"CNS Drugs."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/npp.2014.38","article-title":"Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a \u03b2arrestin2-independent activation of Akt","volume":"39","author":"Schmid","year":"2014","journal-title":"Neuropsychopharmacology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.psyneuen.2019.01.029","article-title":"Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons","volume":"104","author":"Kowalchuk","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"B73","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2015.00092","article-title":"GLP-1 based therapeutics: simultaneously combating T2DM and obesity","volume":"9","author":"Heppner","year":"2015","journal-title":"Front Neurosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/odi.12139","article-title":"Parasympathetic vasoactive intestinal peptide (VIP): a likely contributor to clozapine-induced sialorrhoea","volume":"20","author":"Ekstr\u00f6m","year":"2014","journal-title":"Oral Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00441-019-03067-x","article-title":"The role of oxidative stress in ovarian toxicity induced by haloperidol and clozapine-a histological and biochemical study in albino rats","volume":"378","author":"Khalaf","year":"2019","journal-title":"Cell Tissue Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.psychres.2017.12.018","article-title":"Effect of clozapine dose and concentration on fasting concentration of appetite regulating peptides","volume":"260","author":"Margulska","year":"2018","journal-title":"Psychiatry Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3858\/emm.2012.44.9.062","article-title":"Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics","volume":"44","author":"Oh","year":"2012","journal-title":"Exp Mol Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/S1734-1140(12)70937-4","article-title":"Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - The effect of antipsychotic drugs","volume":"64","author":"Basta-Kaim","year":"2012","journal-title":"Pharmacol Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajp.2019.03.002","article-title":"Clozapine-induced agranulocytosis and leukopenia: incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand","volume":"41","author":"Tunsirimas","year":"2019","journal-title":"Asian J Psychiatr."},{"key":"B80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.rpsm.2016.03.005","article-title":"Increase in white cell and neutrophil counts during the first eighteen weeks of treatment with clozapine in patients admitted to a long-term psychiatric care inpatient unit","volume":"11","author":"Capllonch","year":"2018","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"B81","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-2006-931475","article-title":"In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU)","volume":"39","author":"Pessina","year":"2006","journal-title":"Pharmacopsychiatry."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.2629","article-title":"Human neutrophils show decreased survival upon long-term exposure to clozapine","volume":"32","author":"Goto","year":"2017","journal-title":"Hum Psychopharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1017\/S1461145713001752","article-title":"Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes","volume":"17","author":"Gardiner","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/tpj.2016.32","article-title":"Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population","volume":"17","author":"Van Der Weide","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.psychres.2017.07.002","article-title":"Changes in the cytokine profile in first-episode, drug-na\u00efve patients with psychosis after short-term antipsychotic treatment","volume":"256","author":"Petrikis","year":"2017","journal-title":"Psychiatry Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/J.NEUBIOREV.2017.03.003","article-title":"Acute variations of cytokine levels after antipsychotic treatment in drug-na\u00efve subjects with a first-episode psychosis: a meta-analysis","volume":"77","author":"Capuzzi","year":"2017","journal-title":"Neurosci Biobehav Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1055\/a-0586-8983","article-title":"Clozapine-induced DRESS syndrome: a case series from the AMSP multicenter drug safety surveillance project","volume":"52","author":"Sanader","year":"2019","journal-title":"Pharmacopsychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jneuroim.2006.08.004","article-title":"5-HT1B receptors play a prominent role in the proliferation of T-lymphocytes","volume":"181","author":"Yin","year":"2006","journal-title":"J Neuroimmunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-0842-5","article-title":"Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses","volume":"14","author":"Zareie","year":"2017","journal-title":"J Neuroinflammation."},{"key":"B90","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3109\/08923973.2013.828744","article-title":"Regulation of macrophage immune responses by antipsychotic drugs","volume":"35","author":"Chen","year":"2013","journal-title":"Immunopharmacol Immunotoxicol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e104430","DOI":"10.1371\/journal.pone.0104430","article-title":"Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis","volume":"9","author":"O'Sullivan","year":"2014","journal-title":"PLoS ONE."},{"key":"B92","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40360-017-0171-4","article-title":"Haloperidol affects bones while clozapine alters metabolic parameters - sex specific effects in rats perinatally treated with phencyclidine","volume":"18","author":"Nikoli\u0107","year":"2017","journal-title":"BMC Pharmacol Toxicol."},{"key":"B93","first-page":"59","article-title":"Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers","volume":"52","author":"Szuster-Ciesielska","year":"2004","journal-title":"Arch Immunol Ther Exp."},{"key":"B94","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur Neuropsychopharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00213-015-3976-0","article-title":"Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels","volume":"233","author":"Hefner","year":"2016","journal-title":"Psychopharmacology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/pcn.12508","article-title":"Role of cytokine changes in clozapine-induced fever: a cohort prospective study","volume":"71","author":"Hung","year":"2017","journal-title":"Psychiatry Clin Neurosci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry."},{"key":"B98","first-page":"1027","article-title":"Second generation antipsychotics: pharmacodynamics, therapeutic effects indications and associated metabolic side effects: review of articles","volume":"3","author":"Ayano","year":"2016","journal-title":"J Schizophr Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1021\/acschemneuro.8b00159","article-title":"Classics in chemical neuroscience: risperidone","volume":"9","author":"Chopko","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.parkreldis.2017.08.004","article-title":"The colorful spectrum of tourette syndrome and its medical, surgical and behavioral therapies","volume":"46","author":"Roth","year":"2018","journal-title":"Park Relat Disord."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chc.2019.05.005","article-title":"Psychotropic medication for children and adolescents with eating disorders","volume":"28","author":"Couturier","year":"2019","journal-title":"Child Adolesc Psychiatr Clin N Am."},{"key":"B103","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1684\/PNV.2019.0813","article-title":"Prise en charge pharmacologique des id\u00e9es d\u00e9lirantes associ\u00e9es \u00e0 un syndrome d\u00e9mentiel","volume":"17","author":"Kassm","year":"2019","journal-title":"G\u00e9riatrie Psychol Neuropsychiatr du Vieil."},{"key":"B104","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4021\/jocmr1042w","article-title":"Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment","volume":"4","author":"Belli","year":"2012","journal-title":"J Clin Med Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.639","article-title":"Atypical antipsychotic therapy in Parkinson's disease psychosis: a retrospective study","volume":"7","author":"Yuan","year":"2017","journal-title":"Brain Behav."},{"key":"B106","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1037\/amp0000473","article-title":"Summary of the clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults","volume":"74","author":"Courtois","year":"2019","journal-title":"Am Psychol."},{"key":"B107","volume-title":"Risperidone","author":"McNeil","year":"2019"},{"key":"B108","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/NDT.S14385","article-title":"Clinical utility of the risperidone formulations in the management of schizophrenia","volume":"7","author":"Madaan","year":"2011","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B109","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin Neurosci."},{"key":"B110","first-page":"120","article-title":"Hyperprolactinaemia - a risperidone side-effect","volume":"22","author":"Grahovac","year":"2010","journal-title":"Psychiatr Danub."},{"key":"B111","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.psychres.2016.03.015","article-title":"Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study","volume":"239","author":"Park","year":"2016","journal-title":"Psychiatry Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2017.07.037","article-title":"Hyperprolactinaemia in first episode psychosis - A longitudinal assessment","volume":"189","author":"Lally","year":"2017","journal-title":"Schizophr Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13651501.2019.1576905","article-title":"Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics","volume":"23","author":"Bonete","year":"2019","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/1365150031004786","article-title":"Prolactin levels in risperidone treatment of first-episode schizophrenia","volume":"8","author":"Ce\u0161kov\u00e1","year":"2004","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B115","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"P\u00e9rez-Iglesias","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.psychres.2016.04.001","article-title":"Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia","volume":"240","author":"Charan","year":"2016","journal-title":"Psychiatry Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3969\/j.issn.1002-0829.2014.02","article-title":"Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine","volume":"26","author":"Liu","year":"2014","journal-title":"Shanghai Arch Psychiatry."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.pnpbp.2010.07.003","article-title":"Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients","volume":"34","author":"Suzuki","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B119","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3371\/CSRP.KISE.020113","article-title":"Bone loss associated with hyperprolactinemia in patients with schizophrenia: are there gender differences?","volume":"7","author":"Kinon","year":"2013","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"B120","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.comppsych.2016.08.009","article-title":"Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients","volume":"71","author":"An","year":"2016","journal-title":"Compr Psychiatry."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1248\/bpb.b17-00053","article-title":"Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders","volume":"40","author":"Takechi","year":"2017","journal-title":"Biol Pharm Bull."},{"key":"B122","doi-asserted-by":"publisher","first-page":"FD01","DOI":"10.7860\/JCDR\/2017\/20733.9278","article-title":"Risperidone induced granulomatous mastitis secondary to hyperprolactinemia in a non-pregnant woman-a rare case report in a bipolar disorder","volume":"11","author":"Holla","year":"2017","journal-title":"J Clin Diagnostic Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e1683","DOI":"10.7759\/cureus.1683","article-title":"Risperidone-induced amenorrhea in floridly psychotic female","volume":"9","author":"Shagufta","year":"2017","journal-title":"Cureus."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.2169\/internalmedicine.3224-19","article-title":"Galactorrhea induced by risperidone","volume":"58","author":"Sakaguchi","year":"2020","journal-title":"Intern Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"67","DOI":"10.9758\/cpn.2014.12.1.67","article-title":"A case of acute pancreatitis associated with risperidone treatment","volume":"12","author":"Kawabe","year":"2014","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1708\/3104.30939","article-title":"Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder","volume":"54","author":"Rad","year":"2019","journal-title":"Riv Psichiatr."},{"key":"B127","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/NDT.S76276","article-title":"Hyperprolactinemia in thai children and adolescents with autism spectrum disorder treated with risperidone","volume":"11","author":"Hongkaew","year":"2015","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B128","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/cap.2011.0109","article-title":"Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone","volume":"22","author":"Roke","year":"2012","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YIC.0000000000000063","article-title":"Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents","volume":"30","author":"Margari","year":"2015","journal-title":"Int Clin Psychopharmacol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"543034","DOI":"10.1155\/2018\/1543034","article-title":"Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a network meta-analysis","volume":"2018","author":"Balijepalli","year":"2018","journal-title":"Schizophr Res Treat."},{"key":"B131","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/cap.2015.0094","article-title":"Hyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspects","volume":"25","author":"Dos Santos J\u00fanior","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12881-019-0773-3","article-title":"A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia","volume":"20","author":"Osmanova","year":"2019","journal-title":"BMC Med Genet."},{"key":"B133","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pnpbp.2017.03.009","article-title":"The central mechanism of risperidone-induced hyperprolactinemia","volume":"76","author":"Sun","year":"2017","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B134","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1055\/s-0044-102093","article-title":"Effects of risperidone and aripiprazole on serum levels of prolactin, testosterone and estradiol in female patients with schizophrenia","volume":"68","author":"Jiang","year":"2018","journal-title":"Drug Res."},{"key":"B135","first-page":"548","article-title":"Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia","volume":"8","author":"Piriu","year":"2015","journal-title":"J Med Life."},{"key":"B136","first-page":"50","article-title":"Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics - Olanzapine or risperidone","volume":"35","author":"Konarzewska","year":"2014","journal-title":"Neuroendocrinol Lett."},{"key":"B137","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/2045125312442080","article-title":"Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment","volume":"2","author":"Bishop","year":"2012","journal-title":"Ther Adv Psychopharmacol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/JCP.0b013e318297980e","article-title":"Weight Gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients","volume":"33","author":"Yanik","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/13651501.2010.550400","article-title":"Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls","volume":"15","author":"Tsai","year":"2011","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B140","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000329391","article-title":"Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone","volume":"94","author":"Doknic","year":"2011","journal-title":"Neuroendocrinology."},{"key":"B141","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.clinbiochem.2017.02.003","article-title":"Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders","volume":"50","author":"Srisawasdi","year":"2017","journal-title":"Clin Biochem."},{"key":"B142","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00787-016-0866-x","article-title":"The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study","volume":"26","author":"Baeza","year":"2017","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"B143","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/J.PSYCHRES.2012.03.011","article-title":"Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients","volume":"199","author":"Smith","year":"2012","journal-title":"Psychiatry Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-020-01203-z","article-title":"Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?","volume":"19","author":"Endomba","year":"2020","journal-title":"Lipids Health Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/JCP.0b013e3182524393","article-title":"Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia","volume":"32","author":"Sugai","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaac.2016.02.016","article-title":"Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder","volume":"55","author":"Scahill","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B147","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.euroneuro.2015.06.011","article-title":"Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis","volume":"25","author":"Bartoli","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/cap.2010.0018","article-title":"Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques","volume":"20","author":"Sackett","year":"2010","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.brainres.2014.10.070","article-title":"Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats","volume":"1596","author":"Kursungoz","year":"2015","journal-title":"Brain Res."},{"key":"B151","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/0269881117691466","article-title":"Depot risperidone-induced adverse metabolic alterations in female rats","volume":"31","author":"Horska","year":"2017","journal-title":"J Psychopharmacol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation","volume":"36","author":"Savoy","year":"2010","journal-title":"Schizophr Bull."},{"key":"B153","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.genhosppsych.2012.03.009","article-title":"Risperidone-induced leukopenia: a case report and brief review of literature","volume":"35","author":"Manfredi","year":"2013","journal-title":"Gen Hosp Psychiatry."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu042","article-title":"Effects of risperidone on cytokine profile in drug-na\u00efve first-episode psychosis","volume":"18","author":"Noto","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.toxlet.2017.03.018","article-title":"Effect of antipsychotics on mitochondrial bioenergetics of rat ovarian theca cells","volume":"272","author":"Elmorsy","year":"2017","journal-title":"Toxicol Lett."},{"key":"B156","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1176\/jnp.23.4.jnpe19","article-title":"Neutropenia during risperidone treatment","volume":"23","author":"Tseng","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"B157","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1574886312666170531072837","article-title":"Leukopenia associated with risperidone treatment","volume":"12","author":"Morrison","year":"2017","journal-title":"Curr Drug Saf."},{"key":"B158","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/PRA.0000000000000292","article-title":"Olanzapine-induced and risperidone-induced leukopenia: a case of synergistic adverse reaction?","volume":"24","author":"Sy-Cherng Woon","year":"2018","journal-title":"J Psychiatr Pract."},{"key":"B159","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0004867412460594","article-title":"Risperidone\/paliperidone induced neutropenia and lymphopenia","volume":"47","author":"Raj","year":"2013","journal-title":"Aust N Z J Psychiatry."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.2147\/NDT.S141472","article-title":"Risperidone-induced reversible neutropenia","volume":"13","author":"Kailasam","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B161","first-page":"47","article-title":"Risperidone induced isolated thrombocytopenia: a rare adverse event","volume":"48","author":"Bhattacharjee","year":"2018","journal-title":"Psychopharmacol Bull."},{"key":"B162","first-page":"651","article-title":"Risperidone-induced acute eosinophilic pneumonia","volume":"27","author":"Rizos","year":"2013","journal-title":"In Vivo."},{"key":"B163","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0030-1249071","article-title":"Neutropenia induced by second generation antipsychotics: a prospective investigation","volume":"43","author":"Rettenbacher","year":"2010","journal-title":"Pharmacopsychiatry."},{"key":"B164","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.schres.2010.06.002","article-title":"Possible effects of some antipsychotic drugs on C-reactive protein in a drug-na\u00efve psychotic sample","volume":"121","author":"Diaz","year":"2010","journal-title":"Schizophr Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"E58","DOI":"10.1111\/appy.12078","article-title":"Increased high-sensitivity C-reactive protein levels in Taiwanese schizophrenic patients","volume":"5","author":"Lin","year":"2013","journal-title":"Asia-Pacific Psychiatry."},{"key":"B166","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0091217415610313","article-title":"Elevated risperidone serum concentrations during acute inflammation, two cases","volume":"50","author":"Hefner","year":"2015","journal-title":"Int J Psychiatry Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/sji.12158","article-title":"Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment","volume":"80","author":"Ajami","year":"2014","journal-title":"Scand J Immunol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/08039488.2017.1340518","article-title":"Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study","volume":"71","author":"Kudlek Mikulic","year":"2017","journal-title":"Nord J Psychiatry."},{"key":"B169","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/15622970802309617","article-title":"Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients","volume":"11","author":"Yoshimura","year":"2010","journal-title":"World J Biol Psychiatry."},{"key":"B170","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/a-0869-8053","article-title":"Pathological concentration of c-reactive protein is correlated to increased concentrations of quetiapine, but not of risperidone, olanzapine and aripiprazole in a naturalistic setting","volume":"53","author":"Scherf-Clavel","year":"2019","journal-title":"Pharmacopsychiatry."},{"key":"B171","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/15622970802182733","article-title":"Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics","volume":"11","author":"Rizos","year":"2010","journal-title":"World J Biol Psychiatry."},{"key":"B172","doi-asserted-by":"publisher","first-page":"396","DOI":"10.21037\/atm.2016.10.56","article-title":"Supra-therapeutic plasma concentrations of haloperidol induce moderate inhibition of lipopolysaccharide-induced interleukin-8 release in human monocytes","volume":"4","author":"Bosshart","year":"2016","journal-title":"Ann Transl Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejphar.2010.11.010","article-title":"Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats","volume":"652","author":"McNamara","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.schres.2018.06.039","article-title":"Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-na\u00efve first episode psychosis individuals: a 3 months randomized study","volume":"202","author":"Juncal-Ruiz","year":"2018","journal-title":"Schizophr Res."},{"key":"B175","first-page":"200","article-title":"Serum TNF-\u03b1, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine","volume":"11","author":"Ajami","year":"2014","journal-title":"Iran J Immunol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","article-title":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","volume":"154","author":"De Witte","year":"2014","journal-title":"Schizophr Res."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/rcm.7753","article-title":"Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization\/time-of-flight mass spectrometry","volume":"30","author":"Lo","year":"2016","journal-title":"Rapid Commun Mass Spectrom."},{"key":"B178","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00213-013-3382-4","article-title":"Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na\u00efve, first-episode schizophrenia","volume":"231","author":"Song","year":"2014","journal-title":"Psychopharmacology."},{"key":"B179","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1089\/cap.2013.0108","article-title":"Change in plasma cytokine levels during risperidone treatment in children with autism","volume":"24","author":"Choi","year":"2014","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.intimp.2014.09.030","article-title":"Regulation of neutrophil phagocytosis of Escherichia coli by antipsychotic drugs","volume":"23","author":"Chen","year":"2014","journal-title":"Int Immunopharmacol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"144","DOI":"10.9758\/cpn.2013.11.3.144","article-title":"Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures","volume":"11","author":"Al-Amin","year":"2013","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B182","first-page":"389","article-title":"Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia","volume":"25","author":"Krause","year":"2013","journal-title":"Psychiatr Danub."},{"key":"B183","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.euroneuro.2018.12.008","article-title":"Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis","volume":"29","author":"Noto","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pnpbp.2014.01.001","article-title":"Activation of Th17 cells in drug na\u00efve, first episode schizophrenia","volume":"51","author":"Ding","year":"2014","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","article-title":"Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro","volume":"450","author":"S\u00e1rv\u00e1ri","year":"2014","journal-title":"Biochem Biophys Res Commun."},{"key":"B186","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbi.2016.12.011","article-title":"Antipsychotics influence Toll-like receptor (TLR) expression and its relationship with cognitive functions in schizophrenia","volume":"62","author":"K\u00e9ri","year":"2017","journal-title":"Brain Behav Immun."},{"key":"B187","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jpsychires.2018.11.008","article-title":"Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis","volume":"109","author":"Mantere","year":"2019","journal-title":"J Psychiatr Res."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1139\/cjpp-2013-0185","article-title":"Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats","volume":"91","author":"Aboul-Fotouh","year":"2013","journal-title":"Can J Physiol Pharmacol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00213-015-4079-7","article-title":"Haloperidol and risperidone at high concentrations activate an in vitro inflammatory response of RAW 264.7 macrophage cells by induction of apoptosis and modification of cytokine levels","volume":"233","author":"Da Cruz Jung","year":"2016","journal-title":"Psychopharmacology."},{"key":"B190","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology."},{"key":"B191","unstructured":"Agency for Healthcare Research and Quality (US)Off -Label Use of Atypical Antipsychotic Drugs: A Summary for Clinicians and Policymakers2007"},{"key":"B192","unstructured":"ThomasK\n            SaadabadiA\n          Olanzapine.2019"},{"key":"B193","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/J.RMCR.2014.11.007","article-title":"Olanzapine-induced eosinophilic pleuritis","volume":"14","author":"Evison","year":"2015","journal-title":"Respir Med Case Rep."},{"key":"B194","doi-asserted-by":"publisher","first-page":"e9996","DOI":"10.1097\/MD.0000000000009996","article-title":"Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: a case report","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1021\/tx500183x","article-title":"Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis","volume":"27","author":"Ng","year":"2014","journal-title":"Chem Res Toxicol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00000441-200102000-00008","article-title":"A case report of olanzapine-induced hypersensitivity syndrome","volume":"321","author":"Raz","year":"2001","journal-title":"Am J Med Sci."},{"key":"B197","volume-title":"Olanzapine","author":"Thomas","year":"2019"},{"key":"B198","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4183\/aeb.2018.483","article-title":"Prolactin level in patients with first episode schizophrenia treated for one year with atypical antipsychotics","volume":"14","author":"Matei","year":"2018","journal-title":"Acta Endocrinol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry."},{"key":"B200","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/hup.1110","article-title":"Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients","volume":"25","author":"Yasui-Furukori","year":"2010","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"B201","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3389\/fphar.2019.00846","article-title":"Olanzapine-induced hyperprolactinemia: two case reports","volume":"10","author":"Barata","year":"2019","journal-title":"Front Pharmacol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/J.SCHRES.2012.12.027","article-title":"Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics","volume":"145","author":"Suzuki","year":"2013","journal-title":"Schizophr Res."},{"key":"B203","first-page":"7","article-title":"Serum prolactin levels and the acute-phase efficacy in drug-na\u00efve schizophrenia treated with ziprasidone and olanzapine (translated version)","volume":"22","author":"Wu","year":"2012","journal-title":"East Asian Arch Psychiatry."},{"key":"B204","first-page":"493","article-title":"Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine","volume":"33","author":"Feng","year":"2012","journal-title":"Neuro Endocrinol Lett."},{"key":"B205","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology."},{"key":"B206","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology."},{"key":"B207","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pnpbp.2017.10.021","article-title":"A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients","volume":"81","author":"Huang","year":"2018","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41598-018-36930-y","article-title":"Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance","volume":"9","author":"Li","year":"2019","journal-title":"Sci Rep."},{"key":"B209","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/s-0031-1280793","article-title":"Body mass index increase, serum leptin, adiponectin, neuropeptide y and lipid levels during treatment with olanzapine and haloperidol","volume":"44","author":"Raposo","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"B210","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/J.PNPBP.2018.01.020","article-title":"Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia","volume":"84","author":"Lin","year":"2018","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B211","doi-asserted-by":"publisher","first-page":"e0149518","DOI":"10.1371\/journal.pone.0149518","article-title":"Effect of serum leptin on weight gain induced by olanzapine in female patients with schizophrenia","volume":"11","author":"Tsuneyama","year":"2016","journal-title":"PLoS ONE."},{"key":"B212","doi-asserted-by":"publisher","first-page":"572848","DOI":"10.1155\/2012\/572848","article-title":"The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors","volume":"2012","author":"Panariello","year":"2012","journal-title":"J Obes."},{"key":"B213","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/JCP.0b013e3181f0580e","article-title":"Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis","volume":"30","author":"Basoglu","year":"2010","journal-title":"J Clin Psychopharmacol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.pnpbp.2011.01.010","article-title":"Weight gain and ghrelin level after olanzapine monotherapy","volume":"35","author":"Chen","year":"2011","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B215","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/J.SCHRES.2018.11.036","article-title":"Meta-analysis of ghrelin alterations in schizophrenia: effects of olanzapine","volume":"206","author":"Goetz","year":"2019","journal-title":"Schizophr Res."},{"key":"B216","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18097\/PBMC20186402201","article-title":"The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: Affinity linked mechanism","volume":"64","author":"Zabotina","year":"2018","journal-title":"Biomeditsinskaya Khimiya."},{"key":"B217","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jpsychires.2018.08.017","article-title":"Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells","volume":"105","author":"Stapel","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B218","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/J.PSYNEUEN.2017.04.014","article-title":"Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha","volume":"81","author":"Zhang","year":"2017","journal-title":"Psychoneuroendocrinology."},{"key":"B219","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3892\/etm.2019.7285","article-title":"Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis","volume":"17","author":"Hatziagelaki","year":"2019","journal-title":"Exp Ther Med."},{"key":"B220","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet."},{"key":"B221","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/nedt.2007.3.2.219","article-title":"Quetiapine in the treatment of schizophrenia and related disorders","volume":"3","author":"Riedel","year":"2007","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1248\/cpb.c16-00223","article-title":"Comparative physicochemical and pharmacokinetic properties of quetiapine and its active metabolite norquetiapine","volume":"64","author":"Kim","year":"2016","journal-title":"Chem Pharm Bull."},{"key":"B223","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fpsyt.2013.00102","article-title":"Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders","volume":"4","author":"L\u00f3pez-Mu\u00f1oz","year":"2013","journal-title":"Front Psychiatry."},{"key":"B224","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1017\/S1461145711000824","article-title":"Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release","volume":"15","author":"Carboni","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/0092623X.2011.606883","article-title":"Strategies for the treatment of antipsychotic-induced sexual dysfunction and\/or hyperprolactinemia among patients of the schizophrenia spectrum: a review","volume":"38","author":"Nunes","year":"2012","journal-title":"J Sex Marital Ther."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/0269881108101783","article-title":"Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia","volume":"24","author":"Bushe","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","article-title":"Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study","volume":"34","author":"Oriot","year":"2008","journal-title":"Diabetes Metab."},{"key":"B228","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/JCP.0000000000000118","article-title":"Quetiapine treatment in youth is associated with decreased insulin secretion","volume":"34","author":"Ngai","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B229","first-page":"205","article-title":"The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro","volume":"26","author":"Melkersson","year":"2005","journal-title":"Neuro Endocrinol Lett."},{"key":"B230","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.schres.2011.03.016","article-title":"Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity","volume":"129","author":"McNamara","year":"2011","journal-title":"Schizophr Res."},{"key":"B231","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-018-0711-9","article-title":"Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN","volume":"37","author":"Ran","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia."},{"key":"B233","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/S1461145704004705","article-title":"Neuroendocrine effects of quetiapine in healthy volunteers","volume":"8","author":"De Borja Gon\u00e7alves Guerra","year":"2005","journal-title":"Int J Neuropsychopharmacol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00213-005-0279-x","article-title":"The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects","volume":"185","author":"Cohrs","year":"2006","journal-title":"Psychopharmacology."},{"key":"B235","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WNF.0b013e3181a8cbcc","article-title":"Can quetiapine-induced hypothyroidism be reversible without quetiapine discontinuation?","volume":"32","author":"Kontaxakis","year":"2009","journal-title":"Clin Neuropharmacol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/eip.12134","article-title":"Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report","volume":"9","author":"Cr\u00e9peau-Gendron","year":"2015","journal-title":"Early Interv Psychiatry."},{"key":"B237","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1176\/appi.psy.42.4.368","article-title":"Acute neutropenia in a patient treated with quetiapine","volume":"42","author":"Croarkin","year":"2001","journal-title":"Psychosomatics."},{"key":"B238","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.pnpbp.2006.07.003","article-title":"Leukopenia and neutropenia induced by quetiapine","volume":"31","author":"Cowan","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B239","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1574886313666180807094654","article-title":"Safety of a clozapine trial following quetiapine-induced leukopenia: a case report","volume":"14","author":"Almaghrebi","year":"2019","journal-title":"Curr Drug Saf."},{"key":"B240","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1176\/appi.psy.48.6.530","article-title":"Quetiapine-induced leucopenia and thrombocytopenia","volume":"48","author":"Shankar","year":"2007","journal-title":"Psychosomatics."},{"key":"B241","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5455\/bcp.20151219072235","article-title":"Klinik Psikofarmakoloji B\u00fclteni-bulletin of clinical psychopharmacology neutropenia and thrombocytopenia induced by quetiapine monotherapy: a case report and review of literature","volume":"26","author":"Arslan","year":"2016","journal-title":"Bull Clin Psychopharmacol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","article-title":"Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis","volume":"151","author":"Tourjman","year":"2013","journal-title":"Schizophr Res."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jpsychires.2011.04.009","article-title":"Impact of antipsychotics on cytokine production in-vitro","volume":"45","author":"Himmerich","year":"2011","journal-title":"J Psychiatr Res."},{"key":"B244","doi-asserted-by":"publisher","first-page":"pyu022","DOI":"10.1093\/ijnp\/pyu022","article-title":"Quetiapine attenuates glial activation and proinflammatory cytokines in APP\/PS1 transgenic mice via inhibition of nuclear factor-\u03baB pathway","volume":"18","author":"Zhu","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00018-015-2046-4","article-title":"Neurotrophins and B-cell malignancies","volume":"73","author":"Hillis","year":"2016","journal-title":"Cell Mol Life Sci."},{"key":"B246","first-page":"313","article-title":"The role of neurotrophins in inflammation and allergy","volume-title":"Vitamins and Hormones","author":"Manti","year":""},{"key":"B247","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jad.2014.11.044","article-title":"BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis","volume":"174","author":"Polyakova","year":"2015","journal-title":"J Affect Disord."},{"key":"B248","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jpsychires.2011.03.002","article-title":"Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis","volume":"45","author":"Fernandes","year":"2011","journal-title":"J Psychiatr Res."},{"key":"B249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/719395","article-title":"Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis","volume":"2014","author":"Murphy","year":"2014","journal-title":"Schizophr Res Treat."},{"key":"B250","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.talanta.2010.04.036","article-title":"Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes","volume":"82","author":"Kul","year":"2010","journal-title":"Talanta."},{"key":"B251","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1399-5618.2012.00992.x","article-title":"Maintenance therapies in bipolar disorders","volume":"14","author":"Gitlin","year":"2012","journal-title":"Bipolar Disord."},{"key":"B252","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/ecp.10.139","article-title":"Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review","volume":"4","author":"Sacchetti","year":"2011","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2165\/00023210-200721100-00004","article-title":"Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder","volume":"21","author":"Warrington","year":"2007","journal-title":"CNS Drugs."},{"key":"B254","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur J Pharmacol."},{"key":"B255","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/01.jcp.0000084028.22282.f2","article-title":"Ziprasidone metabolism, aldehyde oxidase, and clinical implications","volume":"23","author":"Beedham","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jad.2012.02.030","article-title":"Antipsychotics in pediatric and adolescent patients: a review of comparative safety data","volume":"138","author":"Ben Amor","year":"2012","journal-title":"J Affect Disord."},{"key":"B257","doi-asserted-by":"publisher","first-page":"PCC","DOI":"10.4088\/PCC.09l00855gry","article-title":"Ziprasidone-induced galactorrhea in an adolescent female: a case report","volume":"12","author":"Raza","year":"2010","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"B258","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4088\/PCC.09l00855gry","article-title":"Ziprasidone-induced galactorrhea: a case report","volume":"26","author":"Kopecek","year":"2005","journal-title":"Neuro Endocrinol Lett."},{"key":"B259","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2125.2005.02431.x","article-title":"Ziprasidone decreases cortisol excretion in healthy subjects","volume":"60","author":"Meier","year":"2005","journal-title":"Br J Clin Pharmacol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.genhosppsych.2005.08.005","article-title":"Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia","volume":"28","author":"Montgomery","year":"2006","journal-title":"Gen Hosp Psychiatry."},{"key":"B261","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/01480545.2016.1252920","article-title":"Ziprasidone induces cytotoxicity and genotoxicity in human peripheral lymphocytes","volume":"40","author":"Kefelioglu","year":"2017","journal-title":"Drug Chem Toxicol."},{"key":"B262","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cyto.2017.10.017","article-title":"Ziprasidone, a second-generation antipsychotic drug, triggers a macrophage inflammatory response in vitro","volume":"106","author":"Duarte","year":"2018","journal-title":"Cytokine."},{"key":"B263","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ajem.2016.11.061","article-title":"Kounis syndrome and ziprasidone","volume":"35","author":"Hamera","year":"2017","journal-title":"Am J Emerg Med."},{"key":"B264","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.pnpbp.2006.01.020","article-title":"Ziprasidone-associated pedal edema in the treatment of schizophrenia","volume":"30","author":"Ku","year":"2006","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B265","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/0269881106075273","article-title":"Urticaria and angio-oedema due to ziprasidone","volume":"21","author":"Akkaya","year":"2007","journal-title":"J Psychopharmacol."},{"key":"B266","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs."},{"key":"B267","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pnpbp.2017.06.023","article-title":"Efficacy, safety and tolerability of aripiprazole in bipolar disorder: an updated systematic review and meta-analysis of randomized controlled trials","volume":"79","author":"Li","year":"2017","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B268","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/YIC.0b013e32835ce232","article-title":"Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006\u20132010)","volume":"28","author":"Jing","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/phe.10.45","article-title":"Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6\u201317 years","volume":"4","author":"Blankenship","year":"2010","journal-title":"Ped Health."},{"key":"B270","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","article-title":"Aripiprazole in schizophrenia and schizoaffective disorder: a review","volume":"32","author":"Stip","year":"2010","journal-title":"Clin Ther."},{"key":"B271","doi-asserted-by":"publisher","first-page":"CD009043","DOI":"10.1002\/14651858.CD009043.pub3","article-title":"Aripiprazole for autism spectrum disorders (ASD)","volume":"26","author":"Hirsch","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B272","first-page":"1346","article-title":"Aripiprazole, alcohol and substance abuse: a review","volume":"16","author":"Brunetti","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B273","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","article-title":"Aripiprazole","volume":"16","author":"McGavin","year":"2002","journal-title":"CNS Drugs."},{"key":"B275","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B276","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/XCE.0000000000000063","article-title":"Atypical antipsychotics and metabolic syndrome","volume":"17","author":"Perez Rodriguez","year":"2015","journal-title":"Cardiovasc Endocrinol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","article-title":"Metabolic syndrome with the atypical antipsychotics","volume":"17","author":"Pramyothin","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"B278","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200519010-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs."},{"key":"B279","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry."},{"key":"B280","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology."},{"key":"B281","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B282","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.schres.2014.09.019","article-title":"Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies","volume":"59","author":"Fleischhacker","year":"2014","journal-title":"Schizophr Res."},{"key":"B283","doi-asserted-by":"publisher","first-page":"e0139717","DOI":"10.1371\/journal.pone.0139717","article-title":"Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS ONE."},{"key":"B284","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"134","author":"Chen","year":"2010","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B285","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0000000000000898","article-title":"Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial","volume":"38","author":"Kelly","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"B286","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1872214807666131229125700","article-title":"Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole","volume":"8","author":"Berardis","year":"2014","journal-title":"Recent Pat Endocr Metab Immune Drug Discov."},{"key":"B287","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0042-116323","article-title":"Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study","volume":"50","author":"Fujioi","year":"2017","journal-title":"Pharmacopsychiatry."},{"key":"B288","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4103\/0253-7176.183082","article-title":"Aripiprazole-induced hyperprolactinemia in a young female with delusional disorder","volume":"38","author":"Joseph","year":"2016","journal-title":"Indian J Psychol Med."},{"key":"B289","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1097\/MJT.0b013e3182456de7","article-title":"Hyperprolactinemia with aripiprazole: understanding the paradox","volume":"21","author":"Saraf","year":"2014","journal-title":"Am J Ther."},{"key":"B290","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jad.2019.03.006","article-title":"Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: a case report","volume":"250","author":"Luo","year":"2019","journal-title":"J Affect Disord."},{"key":"B291","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry."},{"key":"B292","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.schres.2013.01.013","article-title":"Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial","volume":"146","author":"Stroup","year":"2013","journal-title":"Schizophr Res."},{"key":"B293","doi-asserted-by":"publisher","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS ONE."},{"key":"B294","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/acps.12468","article-title":"Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol","volume":"133","author":"Parabiaghi","year":"2016","journal-title":"Acta Psychiatr Scand."},{"key":"B295","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0447.2011.01716.x","article-title":"Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder","volume":"124","author":"Kasteng","year":"2011","journal-title":"Acta Psychiatr Scand."},{"key":"B296","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.neuropharm.2017.06.003","article-title":"Aripiprazole-induced adverse metabolic alterations in polyI: C neurodevelopmental model of schizophrenia in rats","volume":"123","author":"Horska","year":"2017","journal-title":"Neuropharmacology."},{"key":"B297","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3928\/02793695-20180419-02","article-title":"Aripiprazole-induced neutropenia: case report and literature review","volume":"56","author":"Felin","year":"2018","journal-title":"J Psychosoc Nurs Ment Health Serv."},{"key":"B298","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4306\/pi.2013.10.4.428","article-title":"A case with neutropenia related with the use of various atypical antipsychotics","volume":"10","author":"Lim","year":"2013","journal-title":"Psychiatry Investig."},{"key":"B299","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr Res."},{"key":"B300","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pharep.2014.09.007","article-title":"Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity","volume":"67","author":"Sobis","year":"2015","journal-title":"Pharmacol Rep."},{"key":"B301","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.12.006","article-title":"Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic","volume":"148","author":"Yoo","year":"2018","journal-title":"Biochem Pharmacol."},{"key":"B302","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1471-4159.2008.05435.x","article-title":"Inhibitory effects of aripiprazole on interferon-\u03b3-induced microglial activation via intracellular Ca2+ regulation in vitro","volume":"106","author":"Kato","year":"2008","journal-title":"J Neurochem."},{"key":"B303","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12906-018-2169-x","article-title":"Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice","volume":"18","author":"Zargar","year":"2018","journal-title":"BMC Complement Altern Med."},{"key":"B304","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4196\/kjpp.2015.19.4.365","article-title":"Immunotoxicological effects of a ripiprazole: in vivo and in vitro studies","volume":"19","author":"Baek","year":"2015","journal-title":"Korean J Physiol Pharmacol."},{"key":"B305","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1742-1241.2007.01321.x","article-title":"Paliperidone: Quo vadis?","volume":"61","author":"Citrome","year":"2007","journal-title":"Int J Clin Pract."},{"key":"B306","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40120-015-0030-4","article-title":"Paliperidone palmitate for schizoaffective disorder: a review of the clinical evidence","volume":"4","author":"Greenberg","year":"2015","journal-title":"Neurol Ther."},{"key":"B307","unstructured":"Paliperidone Palmitate Product Information"},{"key":"B308","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/schbul\/sbn015","article-title":"Paliperidone for treatment of schizophrenia","volume":"34","author":"Nussbaum","year":"2008","journal-title":"Schizophr Bull."},{"key":"B309","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/NDT.S20675","article-title":"The role of paliperidone extended release for the treatment of bipolar disorder","volume":"2012","author":"Marino","year":"2012","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B310","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/YIC.0000000000000095","article-title":"Effectiveness of long-acting paliperidone palmitate in borderline personality disorder","volume":"30","author":"Palomares","year":"2015","journal-title":"Int Clin Psychopharmacol."},{"key":"B311","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40261-019-00759-8","article-title":"Paliperidone long-acting injections in huntington's disease for motor and behavioural disturbances","volume":"39","author":"van Oosterom","year":"2019","journal-title":"Clin Drug Investig."},{"key":"B312","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000500629","article-title":"Paliperidone use in child psychiatry: evidence or diffidence?","volume":"104","author":"Naguy","year":"2019","journal-title":"Pharmacology."},{"key":"B313","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-013-3073-1","article-title":"A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and \u03b2-cell function in schizophrenic patients","volume":"230","author":"Hu","year":"2013","journal-title":"Psychopharmacology."},{"key":"B314","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12887-016-0710-y","article-title":"Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a systematic review","volume":"16","author":"Druyts","year":"2016","journal-title":"BMC Pediatr."},{"key":"B315","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/10398561003686763","article-title":"Hyperprolactinaemia during treatment with paliperidone","volume":"18","author":"Skopek","year":"2010","journal-title":"Australas Psychiatry."},{"key":"B316","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/YIC.0b013e32835ba832","article-title":"Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate","volume":"28","author":"Montalvo","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"B317","first-page":"28","article-title":"Prolactin levels after switching to paliperidone palmitate in patients with schizophrenia","volume":"13","author":"Nakamura","year":"2016","journal-title":"Innov Clin Neurosci."},{"key":"B318","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/YIC.0000000000000168","article-title":"Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY","volume":"32","author":"Potkin","year":"2017","journal-title":"Int Clin Psychopharmacol."},{"key":"B319","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40263-017-0437-9","article-title":"Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release (ER) for 2 years: a post hoc analysis of an open-label multicenter study","volume":"31","author":"Gopal","year":"2017","journal-title":"CNS Drugs."},{"key":"B320","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bcpt.12570","article-title":"9-Hydroxyrisperidone-induced hyperprolactinaemia in thai children and adolescents with autism spectrum disorder","volume":"119","author":"Ngamsamut","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B321","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-14-52","article-title":"Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate","volume":"2014","author":"Sliwa","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B322","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1805414","article-title":"Paliperidone induced hypoglycemia by increasing insulin secretion","volume":"2016","author":"Omi","year":"2016","journal-title":"Case Rep Psychiatry."},{"key":"B323","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.pnpbp.2010.09.018","article-title":"Paliperidone-induced leukopenia and neutropenia: a case report","volume":"35","author":"Kim","year":"2011","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B324","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1177\/0004867418821441","article-title":"Acute agranulocytosis when switching from risperidone to paliperidone","volume":"53","author":"Wakuda","year":"2019","journal-title":"Aust N Z J Psychiatry."},{"key":"B325","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-016-0874-x","article-title":"Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report","volume":"16","author":"Matsuura","year":"2016","journal-title":"BMC Psychiatry."},{"key":"B326","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry","volume":"23","author":"Flanagan","year":"2008","journal-title":"Hum Psychopharmacol."},{"key":"B327","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.4103\/0366-6999.241802","article-title":"Effects of risperidone and paliperidone on brain-derived neurotrophic factor and N400 in first-episode schizophrenia","volume":"131","author":"Wu","year":"2018","journal-title":"Chin Med J."},{"key":"B328","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1177\/0269881117731169","article-title":"Associations of fatty acids with cognition, psychopathology, and brain-derived neurotrophic factor levels in patients with first-episode schizophrenia and related disorders treated with paliperidone extended release","volume":"31","author":"Chung","year":"2017","journal-title":"J Psychopharmacol."},{"key":"B329","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/tpj.2014.84","article-title":"Network analysis of gene expression in peripheral blood identifies mTOR and NF-\u03baB pathways involved in antipsychotic-induced extrapyramidal symptoms","volume":"15","author":"Mas","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"B330","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0269881108096506","article-title":"Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro","volume":"24","author":"Schmidt","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B331","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"B332","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40261-017-0592-2","article-title":"A review of asenapine in the treatment of bipolar disorder","volume":"38","author":"Vieta","year":"2018","journal-title":"Clin Drug Investig."},{"key":"B333","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1039\/c5ob02047f","article-title":"The Ireland-claisen rearrangement strategy towards the synthesis of the schizophrenia drug, (+)-asenapine","volume":"14","author":"Anugu","year":"2016","journal-title":"Org Biomol Chem."},{"key":"B334","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1124\/dmd.110.036715","article-title":"Metabolism and excretion of asenapine in healthy male subjects","volume":"39","author":"van de Wetering-Krebbers","year":"2011","journal-title":"Drug Metab Dispos."},{"key":"B335","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1021\/acs.jmedchem.7b01220","article-title":"From the promiscuous asenapine to potent fluorescent ligands acting at a series of aminergic G-protein-coupled receptors","volume":"61","author":"Hounsou","year":"2018","journal-title":"J Med Chem."},{"key":"B336","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/cns.12698","article-title":"Asenapine modulates mood-related behaviors and 5-HT1A\/7 receptors-mediated neurotransmission","volume":"23","author":"Delcourte","year":"2017","journal-title":"CNS Neurosci Ther."},{"key":"B337","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol."},{"key":"B338","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/ecp.12.70","article-title":"Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults","volume":"6","author":"Bobo","year":"2013","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B339","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622312468933","article-title":"Asenapine in bipolar I disorder: evidence and place in patient management","volume":"4","author":"Samalin","year":"2013","journal-title":"Ther Adv Chronic Dis."},{"key":"B340","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs."},{"key":"B341","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1176\/appi.ajp.2013.13050650","article-title":"Antipsychotic treatment in breast cancer patients","volume":"171","author":"Rahman","year":"2014","journal-title":"Am J Psychiatry."},{"key":"B342","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1517\/14740338.2014.908183","article-title":"Asenapine review, part II: clinical efficacy, safety and tolerability","volume":"13","author":"Citrome","year":"2014","journal-title":"Expert Opin Drug Saf."},{"key":"B343","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/NDT.S16077","article-title":"Role of sublingual asenapine in treatment of schizophrenia","volume":"7","author":"Citrome","year":"2011","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B344","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaac.2015.09.007","article-title":"Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar i disorder","volume":"54","author":"Findling","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B345","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00011-018-1140-0","article-title":"The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4\/MIP-1\u03b2 from fully differentiated M1 macrophages","volume":"67","author":"Mommert","year":"2018","journal-title":"Inflamm Res."},{"key":"B346","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1164\/ajrccm.157.3.9704071","article-title":"Variability of peripheral blood lymphocyte beta-2-adrenergic receptor density in humans","volume":"157","author":"Anstead","year":"1998","journal-title":"Am J Respir Crit Care Med."},{"key":"B347","first-page":"1050","article-title":"Pityriasis rosea-like drug reaction to asenapine","volume":"12","author":"Makdisi","year":"2013","journal-title":"J Drugs Dermatol."},{"key":"B348","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/08039488.2016.1230649","article-title":"Resistin as an inflammatorymarker in patients with schizophrenia treated with clozapine","volume":"71","author":"Klemettil\u00e4","year":"2017","journal-title":"Nord J Psychiatry."},{"key":"B349","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00213-018-5102-6","article-title":"Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome","volume":"236","author":"Skonieczna-Zydecka","year":"2019","journal-title":"Psychopharmacology."},{"key":"B350","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41398-018-0116-8","article-title":"Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota","volume":"8","author":"Kao","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B351","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.schres.2018.05.017","article-title":"Changes in metabolism and microbiota after 24-week risperidone treatment in drug na\u00efve, normal weight patients with first episode schizophrenia","volume":"201","author":"Yuan","year":"2018","journal-title":"Schizophr Res."},{"key":"B352","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","article-title":"Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure","volume":"2","author":"Bahra","year":"2015","journal-title":"EBioMedicine."},{"key":"B353","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1038\/tp.2015.135","article-title":"Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children","volume":"5","author":"Bahr","year":"2015","journal-title":"Transl Psychiatry."},{"key":"B354","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1038\/tp.2013.83","article-title":"Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat","volume":"3","author":"Davey","year":"2013","journal-title":"Transl Psychiatry."},{"key":"B355","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00213-018-5006-5","article-title":"Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function","volume":"236","author":"Cussotto","year":"2019","journal-title":"Psychopharmacology."},{"key":"B356","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1124\/dmd.118.081026","article-title":"An ex vivo fermentation screening platform to study drug metabolism by human gut microbiota","volume":"46","author":"van de Steeg","year":"2018","journal-title":"Drug Metab Dispos."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T05:19:48Z","timestamp":1587446388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":356,"alternative-id":["10.3389\/fendo.2020.00195"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00195","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"article-number":"195"}}